Table 2 Efficacy results of candidate vaccines for active immunization against respiratory syncytial virus
| Class | Vaccine structure | Clinical trial phase | Results |
|---|---|---|---|
| Live attenuated[74] |
rA2cp248/404ΔNS2 rA2cp530/1009 Δ NS2 | I |
- Not infectious in adults - Well tolerated, no symptomatic illness - Infected 50% and 20% sero-negative infants respectively at a dose of 105 pfu |
| Live attenuated[24] | rA2cpts248/404/1030/ Δ SH | I |
- only candidate with a demonstrated safety profile - 44% vaccinated infants had detectable antibodies after 2 doses of 5.3log10 pfu |
| b/hPIV3/RSVF2[44] | Recombinant attenuated para-influenza virus type-3 expressing RSV-F protein | I |
- tested in 120 1-9 year old sero-positive children. - acceptable safety profile - minimally immunogenic |
| Subunit[32, 75, 76] | Purified F Protein - PFP 1 and PFP 2 | Discontinued after phase I/ II |
- Pilot study shows significant antibody titres in children with CF - Safe and immunogenic in 12-48 month old sero-positive children |
| Subunit[75, 76] | PFP 3 | Discontinued after phase II |
- Double blinded controlled multi-centre study in CF children - Safe and immunogenic but no reduction in LRTI |
| Subunit[75, 76] | BBG2Na | Animal models |
- Safe and immunogenic in adult mice. - Phase III trials in adult volunteers stopped due to unexpected adverse effects24 |
